peyona (previously nymusa)
chiesi farmaceutici spa - caffeine citrate - apnea - psychoanaleptics, - treatment of primary apnoea of premature newborns.
tovanor breezhaler
novartis europharm limited - glycopyrronium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - tovanor breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).
atovaquone/proguanil hydrochloride 250 mg /100 mg film-coated tablets
glenmark pharmaceuticals europe limited - atovaquone; proguanil hydrochloride - film-coated tablet - 250 mg/100 milligram(s) - biguanides; proguanil, combinations
zaxine tablet
salix pharmaceuticals inc - rifaximin - tablet - 550mg - rifaximin 550mg - rifamycins
levocarnitine tablet
akorn - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 330 mg - levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known.
cozaar 100mg tablets
sigma pharmaceuticals plc - losartan potassium - oral tablet - 100mg
colistimethate 1million unit powder for solution for injection vials
kent pharma (uk) ltd - colistimethate sodium - powder for solution for injection - 1000000unit
peyona 20mgml solution for infusion ampoules
chiesi ltd - caffeine citrate - solution for infusion - 20mg/1ml
quofenix
a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - community-acquired infections - antibacterials for systemic use, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.
atovaquone/proguanil hydrochloride 250 mg /100 mg film-coated tablets
glenmark arzneimittel gmbh - atovaquone; proguanil hydrochloride - film-coated tablet - 250 mg/100 milligram(s) - biguanides; proguanil, combinations